Funder
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Fundação de Amparo à Pesquisa do Estado de São Paulo
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Hayward C, Patel HC, Patel K, Di Mario C, Lyon AR, Ahsan SY, et al. The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998–2014. Eur Heart J Cardiovasc Pharmacother. 2016;2(2):90–4.
2. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9(9):CD005049.
3. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35(1):13–29.
4. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.
5. Wu Z, Zhou P, He N, Zhai S. Drug-induced torsades de pointes: disproportionality analysis of the United States Food and Drug Administration adverse event reporting system. Front Cardiovasc Med. 2022;9:966331.